“2025 was a successful year for Sartorius: We delivered on our full-year targets and demonstrated that we are continuing on our profitable growth path. In 2025, we saw several dynamics at play: Ordering behavior for consumables returned to more normal levels and customer innovation gained momentum. In contrast, investment decisions remained cautious amid a challenging market environment, driven mainly by geopolitical risks and trade policy uncertainties. [...] As we head into 2026, let’s keep building on our strengths, stay curious, and be bold in exploring new ways to support our customers. Our goal remains clear: to set new standards in biopharma by delivering outstanding solutions and experiences for our customers."
Sales revenue
€3,538.1m
+7.6% in constant currencies
Underlying EBITDA
€1,051.6m
+11.2%
Underlying EBITDA Margin
29.7%
+1.7 pp
Employees
14,042
+514
Market capitalization
~€15.1bn
Group Business Development and Divisions
The Sartorius Group recorded clear, profitable growth in fiscal year 2025. The positive development was driven by significant growth in the larger and higher-margin recurring business with consumables. As expected, the continued industry-wide investment restraint by customers had a dampening effect on the laboratory instruments and bioprocess equipment business, although this area increasingly stabilized over the course of the year.
Group Business Development
Bioprocess Solutions
In the Bioprocess Solutions Division, Sartorius offers a broad product portfolio that covers all steps in the production of a biopharmaceutical. The company has held leading market positions for years in its core technologies, such as filtration, fermentation, cell cultivation and fluid management.
Lab Products & Services
The Lab Products & Services Division offers laboratories in the pharmaceutical and biopharmaceutical industries as well as at academic research institutes innovative solutions for bioanalytics, in addition to premium laboratory products, consumables and services. Sartorius is among the market leaders in laboratory balances, pipettes and lab consumables.
Outlook
All forecast figures are based on constant currencies, as in past years. Management points out that the dynamics and volatilities in the industry have increased significantly in recent years. In addition, uncertainties due to the changed geopolitical situation, such as the emerging decoupling tendencies of various countries as well as the trade policy framework conditions, are playing a greater role. This results in higher uncertainty when forecasting business figures.
Forecast
For fiscal 2026, Sartorius expects its profitable growth trajectory to continue, with the Bioprocess Solutions division continuing to perform well and a recovery in the Lab Products & Services division. Management forecasts the Sartorius Group’s sales revenue growth in constant currencies to be between around 5 and 9 percent, including a contribution of approximately 1 percentage point from the MATTEK acquisition and US tariff surcharges.
Downloads and Service
Investor Relations Contacts
